MindBio Therapeutics Corp.
MBIO
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1,951.95% | 2,548.11% | 967.74% | -54.66% | -4.71% |
| Depreciation & Amortization | -- | -- | 2.74% | -- | 83.49% |
| Other Operating Expenses | -- | -3.93% | -- | -- | -- |
| Total Operating Expenses | 1,070.80% | 1,579.96% | 2,447.52% | -61.93% | 20.07% |
| Operating Income | -1,070.80% | -1,579.96% | -114.96% | -152.16% | -910.84% |
| Income Before Tax | -534.12% | -2,507.26% | -436.66% | -1,271.68% | -857.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -534.12% | -2,507.26% | -436.66% | -1,271.68% | -857.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -117.86% | 25.00% | -- | -- | -- |
| Net Income | -541.50% | -2,474.27% | -438.53% | -1,269.90% | -847.13% |
| EBIT | -1,070.80% | -1,579.96% | -114.96% | -152.16% | -910.84% |
| EBITDA | -- | -- | -- | -142.77% | -319.75% |
| EPS Basic | -53,655.00% | -725.74% | -1.95% | -1,245.05% | 98.08% |
| Normalized Basic EPS | -55,908.33% | -719.94% | -37.05% | -290.51% | 98.16% |
| EPS Diluted | -53,655.00% | -725.74% | -1.95% | -1,245.05% | 98.08% |
| Normalized Diluted EPS | -20,383.33% | -719.94% | -37.05% | -290.51% | 98.16% |
| Average Basic Shares Outstanding | -98.83% | 211.81% | 428.32% | 2.16% | 50,377.17% |
| Average Diluted Shares Outstanding | -96.81% | 211.81% | 428.32% | 2.16% | 50,377.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |